Literature DB >> 9729046

Probing immunoglobulin gene hypermutation with microsatellites suggests a nonreplicative short patch DNA synthesis process.

B Bertocci1, L Quint, F Delbos, C Garcia, C A Reynaud, J C Weill.   

Abstract

As the rate of Ig gene hypermutation approximates the level of nucleotide discrimination of DNA polymerases (10(-3) to 10(-4)), a local inhibition of proofreading and mismatch repair during semiconservative replication could generate the mutations introduced by the process. To address this question, we have constructed transgenic mice that carry a hypermutation substrate containing a "polymerase slippage trap": an Ig gene with a mono or dinucleotide tract inserted in its V region. The low amount of slippage events as compared to the number of mutations, the absence of transient misalignment mutations at the border of the repeats, and the dissociation between the amount of frameshifts and mutations when the transgene is put on mismatch repair-deficient genetic backgrounds, suggest that Ig gene hypermutation occurs by an error-prone short patch DNA synthesis taking place outside global DNA replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9729046     DOI: 10.1016/s1074-7613(00)80608-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  16 in total

Review 1.  Transcription, beta-like DNA polymerases and hypermutation.

Authors:  C A Reynaud; S Frey; S Aoufouchi; A Faili; B Bertocci; A Dahan; E Flatter; F Delbos; S Storck; C Zober; J C Weill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

Review 2.  Somatic immunoglobulin hypermutation.

Authors:  Marilyn Diaz; Paolo Casali
Journal:  Curr Opin Immunol       Date:  2002-04       Impact factor: 7.486

3.  The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation.

Authors:  H Zan; A Komori; Z Li; A Cerutti; A Schaffer; M F Flajnik; M Diaz; P Casali
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

4.  Two novel human and mouse DNA polymerases of the polX family.

Authors:  S Aoufouchi; E Flatter; A Dahan; A Faili; B Bertocci; S Storck; F Delbos; L Cocea; N Gupta; J C Weill; C A Reynaud
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

5.  An experimental solution for the Luria-Delbrück fluctuation problem in measuring hypermutation rates.

Authors:  J Bachl; M Dessing; C Olsson; R C von Borstel; C Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

6.  Mice reconstituted with DNA polymerase beta-deficient fetal liver cells are able to mount a T cell-dependent immune response and mutate their Ig genes normally.

Authors:  G Esposito; G Texido; U A Betz; H Gu; W Müller; U Klein; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

7.  Correlation of somatic hypermutation specificity and A-T base pair substitution errors by DNA polymerase eta during copying of a mouse immunoglobulin kappa light chain transgene.

Authors:  Youri I Pavlov; Igor B Rogozin; Alexey P Galkin; Anna Y Aksenova; Fumio Hanaoka; Christina Rada; Thomas A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

8.  DNA polymerase mu (Pol mu), homologous to TdT, could act as a DNA mutator in eukaryotic cells.

Authors:  O Domínguez; J F Ruiz; T Laín de Lera; M García-Díaz; M A González; T Kirchhoff; C Martínez-A; A Bernad; L Blanco
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

9.  Highly frequent frameshift DNA synthesis by human DNA polymerase mu.

Authors:  Y Zhang; X Wu; F Yuan; Z Xie; Z Wang
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

10.  DNA polymerase mu gene expression in B-cell non-Hodgkin's lymphomas: an analysis utilizing in situ hybridization.

Authors:  April Chiu; Langxing Pan; Zongdong Li; Scott Ely; Amy Chadburn; Daniel M Knowles
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.